vs
Side-by-side financial comparison of Albemarle Corporation (ALB) and Astrana Health, Inc. (ASTH). Click either name above to swap in a different company.
Albemarle Corporation is the larger business by last-quarter revenue ($1.4B vs $950.5M, roughly 1.5× Astrana Health, Inc.). Astrana Health, Inc. runs the higher net margin — 0.7% vs -29.0%, a 29.7% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 15.9%). Albemarle Corporation produced more free cash flow last quarter ($233.1M vs $-6.0M). Over the past eight quarters, Astrana Health, Inc.'s revenue compounded faster (53.3% CAGR vs 2.4%).
Albemarle Corporation develops, manufactures, and markets engineered specialty chemicals worldwide. It operates through three segments: Lithium, Bromine, and Catalysts. The Lithium segment offers lithium compounds, including lithium carbonate, lithium hydroxide, lithium chloride, and lithium specialties; and reagents, such as butyllithium and lithium aluminum hydride for use in lithium batteries for consumer electronics and electric vehicles, high performance greases, thermoplastic elastomers...
Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.
ALB vs ASTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.4B | $950.5M |
| Net Profit | $-414.2M | $6.6M |
| Gross Margin | 13.9% | — |
| Operating Margin | -15.2% | 1.9% |
| Net Margin | -29.0% | 0.7% |
| Revenue YoY | 15.9% | 42.9% |
| Net Profit YoY | -650.1% | 184.4% |
| EPS (diluted) | $-3.88 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.4B | $950.5M | ||
| Q3 25 | $1.3B | $956.0M | ||
| Q2 25 | $1.3B | $654.8M | ||
| Q1 25 | $1.1B | $620.4M | ||
| Q4 24 | $1.2B | $665.2M | ||
| Q3 24 | $1.4B | $478.7M | ||
| Q2 24 | $1.4B | $486.3M | ||
| Q1 24 | $1.4B | $404.4M |
| Q4 25 | $-414.2M | $6.6M | ||
| Q3 25 | $-160.7M | $373.0K | ||
| Q2 25 | $22.9M | $9.4M | ||
| Q1 25 | $41.3M | $6.7M | ||
| Q4 24 | $75.3M | $-7.8M | ||
| Q3 24 | $-1.1B | $16.1M | ||
| Q2 24 | $-188.2M | $19.2M | ||
| Q1 24 | $2.4M | $14.8M |
| Q4 25 | 13.9% | — | ||
| Q3 25 | 9.0% | — | ||
| Q2 25 | 14.8% | — | ||
| Q1 25 | 14.5% | — | ||
| Q4 24 | 11.2% | — | ||
| Q3 24 | -7.7% | — | ||
| Q2 24 | -0.7% | — | ||
| Q1 24 | 2.9% | — |
| Q4 25 | -15.2% | 1.9% | ||
| Q3 25 | -16.6% | 2.0% | ||
| Q2 25 | 3.6% | 3.1% | ||
| Q1 25 | 1.8% | 3.3% | ||
| Q4 24 | 0.4% | 0.1% | ||
| Q3 24 | -81.9% | 5.9% | ||
| Q2 24 | -34.4% | 6.2% | ||
| Q1 24 | -13.2% | 7.5% |
| Q4 25 | -29.0% | 0.7% | ||
| Q3 25 | -12.3% | 0.0% | ||
| Q2 25 | 1.7% | 1.4% | ||
| Q1 25 | 3.8% | 1.1% | ||
| Q4 24 | 6.1% | -1.2% | ||
| Q3 24 | -78.9% | 3.4% | ||
| Q2 24 | -13.2% | 3.9% | ||
| Q1 24 | 0.2% | 3.7% |
| Q4 25 | $-3.88 | $0.12 | ||
| Q3 25 | $-1.72 | $0.01 | ||
| Q2 25 | $-0.16 | $0.19 | ||
| Q1 25 | $0.00 | $0.14 | ||
| Q4 24 | $0.29 | $-0.14 | ||
| Q3 24 | $-9.45 | $0.33 | ||
| Q2 24 | $-1.96 | $0.40 | ||
| Q1 24 | $-0.08 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $429.5M |
| Total DebtLower is stronger | $3.2B | — |
| Stockholders' EquityBook value | $9.5B | $779.3M |
| Total Assets | $16.4B | $2.2B |
| Debt / EquityLower = less leverage | 0.33× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $429.5M | ||
| Q3 25 | $1.9B | $463.4M | ||
| Q2 25 | $1.8B | $342.1M | ||
| Q1 25 | $1.5B | $260.9M | ||
| Q4 24 | $1.2B | $290.8M | ||
| Q3 24 | $1.7B | $350.3M | ||
| Q2 24 | $1.8B | $327.7M | ||
| Q1 24 | $2.1B | $337.3M |
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.6B | — | ||
| Q2 25 | $3.6B | — | ||
| Q1 25 | $3.5B | — | ||
| Q4 24 | $3.5B | — | ||
| Q3 24 | $3.6B | — | ||
| Q2 24 | $3.5B | — | ||
| Q1 24 | $3.5B | — |
| Q4 25 | $9.5B | $779.3M | ||
| Q3 25 | $10.0B | $775.5M | ||
| Q2 25 | $10.2B | $765.5M | ||
| Q1 25 | $10.0B | $745.4M | ||
| Q4 24 | $10.0B | $712.7M | ||
| Q3 24 | $10.2B | $704.6M | ||
| Q2 24 | $11.2B | $678.9M | ||
| Q1 24 | $11.5B | $653.5M |
| Q4 25 | $16.4B | $2.2B | ||
| Q3 25 | $17.1B | $2.2B | ||
| Q2 25 | $17.3B | $1.4B | ||
| Q1 25 | $17.0B | $1.3B | ||
| Q4 24 | $16.6B | $1.4B | ||
| Q3 24 | $17.5B | $1.3B | ||
| Q2 24 | $18.4B | $1.3B | ||
| Q1 24 | $19.0B | $1.2B |
| Q4 25 | 0.33× | — | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.35× | — | ||
| Q4 24 | 0.35× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | 0.31× | — | ||
| Q1 24 | 0.31× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $388.5M | $-2.9M |
| Free Cash FlowOCF − Capex | $233.1M | $-6.0M |
| FCF MarginFCF / Revenue | 16.3% | -0.6% |
| Capex IntensityCapex / Revenue | 10.9% | 0.3% |
| Cash ConversionOCF / Net Profit | — | -0.44× |
| TTM Free Cash FlowTrailing 4 quarters | $692.5M | $104.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $388.5M | $-2.9M | ||
| Q3 25 | $355.6M | $10.0M | ||
| Q2 25 | $-7.2M | $90.9M | ||
| Q1 25 | $545.4M | $16.6M | ||
| Q4 24 | $674.0K | $-10.9M | ||
| Q3 24 | $240.5M | $34.0M | ||
| Q2 24 | $362.9M | $23.2M | ||
| Q1 24 | $98.0M | $6.0M |
| Q4 25 | $233.1M | $-6.0M | ||
| Q3 25 | $223.4M | $7.4M | ||
| Q2 25 | $-126.8M | $89.5M | ||
| Q1 25 | $362.8M | $13.6M | ||
| Q4 24 | $-355.1M | $-13.5M | ||
| Q3 24 | $-62.6M | $31.7M | ||
| Q2 24 | $-84.7M | $20.4M | ||
| Q1 24 | $-481.4M | $5.6M |
| Q4 25 | 16.3% | -0.6% | ||
| Q3 25 | 17.1% | 0.8% | ||
| Q2 25 | -9.5% | 13.7% | ||
| Q1 25 | 33.7% | 2.2% | ||
| Q4 24 | -28.8% | -2.0% | ||
| Q3 24 | -4.6% | 6.6% | ||
| Q2 24 | -5.9% | 4.2% | ||
| Q1 24 | -35.4% | 1.4% |
| Q4 25 | 10.9% | 0.3% | ||
| Q3 25 | 10.1% | 0.3% | ||
| Q2 25 | 9.0% | 0.2% | ||
| Q1 25 | 17.0% | 0.5% | ||
| Q4 24 | 28.9% | 0.4% | ||
| Q3 24 | 22.4% | 0.5% | ||
| Q2 24 | 31.3% | 0.6% | ||
| Q1 24 | 42.6% | 0.1% |
| Q4 25 | — | -0.44× | ||
| Q3 25 | — | 26.69× | ||
| Q2 25 | -0.31× | 9.65× | ||
| Q1 25 | 13.19× | 2.48× | ||
| Q4 24 | 0.01× | — | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 1.21× | ||
| Q1 24 | 40.01× | 0.40× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ALB
| Energy Storage | $759.1M | 53% |
| Specialties | $348.9M | 24% |
| Ketjen | $320.1M | 22% |
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
